VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 13, 2022
BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference (Hybrid) on September 13, 2022. Management will also be available for one-on-one meetings with investors.
H.C. Wainwright 24th Annual Global Investment Conference – Presentation Details
| Date: | Tuesday, September 13, 2022 |
| Time: | 12:30 p.m. ET |
| Format: | Company Presentation |
| Presenter: | David Domzalski, President and Chief Executive Officer of VYNE |
| Webcast Link: | To attend, please register . |
| *a replay will be available on the VYNE website for 90 days following the presentation |
Please contact your H.C. Wainwright & Co. representative if you would like to schedule a one-on-one meeting during the conference.
For more information about the H.C. Wainwright 24th Annual Global Investment Conference, please refer to the .
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary bromodomain & extra-terminal (BET) domain platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi), and access to a library of small molecule BET inhibitors for the potential treatment of immuno-inflammatory conditions licensed from Tay Therapeutics Limited.
For more information about VYNE Therapeutics Inc. or its investigational products, visit . VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
